Venture Capital Firms face investment requests from increasing numbers of biotechnology start-up companies as these companies enter more expensive stages of development. Our experience in basic, preclinical and clinical research can facilitate your evaluation of potential investment opportunities in the life sciences, biotechnology, and pharmaceutical industries, and assist your identification of both high value companies and high value therapeutic candidates.
The Camden Group has the knowledge and perspective to:
Assess clinical feasibility from analysis of preclinical and early clinical data.
Direct resources to those programs most likely to succeed.
Optimize clinical development programs and timelines. The clinical programs we previously led were at the industry benchmark for speed from First-in-Man to initiation of Phase III.
Perform in-depth analyses of existing preclinical and clinical development programs, identify gaps, and create stream-lined programs to accelerate NDA/PLA submissions.
